Why Is UNITED THERAPEUTICS (UTHR) Stock Down Today?
By the Top Tier Newswire AI Desk · September 2, 2026 at 11:44 AM ET · reviewed against 4 wire stories
UNITED THERAPEUTICS (UTHR) is down -5.20% in the latest session. Our newswire has captured 4 stories on UTHR across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why UTHR stock is down today
United Therapeutics (UTHR) stock fell 5.20% to $486.03 in early trading on Friday as the market digested the implications of recent developments in the company's regulatory and strategic initiatives. The FDA accepted a supplemental New Drug Application (sNDA) for nebulized Tyvaso to treat idiopathic pulmonary fibrosis. While this acceptance is a procedural milestone, the stock declined as investors weighed the timeline and potential market impact of the label expansion.
What Happened
The FDA accepted United Therapeutics' sNDA for nebulized Tyvaso, a formulation of its flagship product, to treat idiopathic pulmonary fibrosis. This follows a broader regulatory agenda that includes an NDA for ralinepag in pulmonary arterial hypertension and the completion of the TETON-PPF study evaluating Tyvaso for progressive pulmonary fibrosis. The company also announced plans for CEO Martine Rothblatt to present at investor conferences in Boston and New York, with webcasts available for 90 days after each session. The CEO has sold shares on multiple occasions in late August, including on August 27, 28, and 31. These insider sales may have contributed to investor caution.
What The Data Shows
The stock opened at $510.00, a 0.5% gap down from the previous close of $512.70. It reached a high of $510.05 at 9:30 AM ET but fell to a low of $483.97 at 11:40 AM ET. Volume so far stands at 0.1 million shares, which is 0.3 times the 3-month daily average. The stock is trading within its 52-week range of $375.61 to $609.35. The market cap is $21.9 billion, with a P/E ratio of 18.3 and a beta of 0.56. United Therapeutics has posted a 2.5% year-to-date revenue increase and a net margin of 41.6%. The stock has printed 22 fresh 52-week lows on September 2.
What To Watch
Investors should monitor the company’s upcoming investor conference presentations and the progress of its regulatory submissions, including the PDUFA target action date of June 24, 2027 for ralinepag. The label expansion for nebulized Tyvaso is expected to be reviewed late April 2027.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
UTHR · Sep 2 session (5-min) · -4.03% vs prior close · updated 8:45 PM ETAI sentiment, last 36h · averaged over 4 stories · 63/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
11d agoSeeking AlphaBULLISH 68Product/PR
United Therapeutics bid to expand nebulized Tyvaso label gets FDA review
United Therapeutics (UTHR) stock gains as the FDA accepts its bid seeking a U.S. label expansion for a nebulized version of its lead product, Tyvaso. Read more here.
11d agoThe FlyBULLISH 63Product/PR
United Therapeutics announces FDA accepted sNDA for Tyvaso
11d agoStockTitanBULLISH 63Product/PR
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
12d agoStockTitanBULLISH 56General
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
CEO Martine Rothblatt presents in Boston and New York, with live webcasts and archived recordings available about 24 hours after each session for 90 days.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →